Market Performance: The Hang Seng Index (HSI) rose by 359 points (1.4%) to close at 25,417, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw gains of 108 points (1.9%) and 120 points (1.3%) respectively, with a total market turnover of $299.95 billion.
Active Heavyweights: Notable stock movements included TENCENT (+2.2% to $605.5), MEITUAN (+1.6% to $103), and BABA (+1.5% to $131.8), with significant short selling activity observed across these stocks.
Top Gainers: XINYI SOLAR surged by 7.5% to $3.71, SINO BIOPHARM increased by 6.2% to $8.91, and HANG LUNG PPT rose by 6.1% to $8.49, among other notable gainers in the market.
High Performers in HSMI & HSSI: CALB and 3SBIO both achieved significant gains of over 18%, closing at $29.26 and $35.66 respectively, with several other stocks also hitting new highs during the trading session.
00101
$8.94+Infinity%1D
Analyst Views on 00101
Wall Street analysts forecast 00101 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00101 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 00101 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00101 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 8.930
Low
Averages
High
Current: 8.930
Low
Averages
High
CICC
CICC
Outperform
maintain
$9.46
2025-12-11
Reason
CICC
CICC
Price Target
$9.46
2025-12-11
maintain
Outperform
Reason
The analyst rating for HANG LUNG PPT (00101.HK) is an "Outperform" based on several key factors highlighted in the article. The partnership with Wuxi Liangxi Urban Development Company to acquire operating rights for a significant commercial project is seen as a strategic move that aligns with the company's Hang Lung V.3 strategy, which emphasizes high capital efficiency and selective reinvestment in existing projects. Additionally, CICC expects the retail sales performance of HANG LUNG PPT's malls in China to maintain positive momentum, projecting a 10% year-over-year growth in retail sales for 3Q25. These factors contribute to the positive outlook and the target price of HKD9.46 set by CICC.
JPMorgan
JPMorgan
maintain
$10
2025-12-11
Reason
JPMorgan
JPMorgan
Price Target
$10
2025-12-11
maintain
Reason
The analyst rating for HANG LUNG PPT (00101.HK) is based on several key factors highlighted in the article. JPMorgan reaffirmed the stock as one of its top picks due to the continuous improvement in tenant sales in mainland China, with expectations of a 10% year-over-year growth in sales for the fourth quarter of 2025, following similar growth in the third quarter. Additionally, the company's recent acquisition of operational rights for a commercial project in Wuxi aligns with its HLP V.3 growth strategy, indicating a proactive approach to expansion. Despite a focus on debt reduction in the near term, JPMorgan believes the company can still identify growth drivers in a lower-risk manner. Consequently, they rated HANG LUNG PPT as Overweight, with a target price of $10 for June 2026.
UBS
UBS
Neutral -> Buy
upgrade
2025-10-17
Reason
UBS
UBS
Price Target
2025-10-17
upgrade
Neutral -> Buy
Reason
The analyst rating from the article is primarily driven by signs of recovery in luxury and jewelry sales in Mainland China and Hong Kong, attributed to the wealth effect from the stock market and higher gold prices. UBS upgraded CHINA RES MIXC from Neutral to Buy due to its higher proportion of emerging brands and the positive outlook for luxury retail in Hong Kong, which is benefiting from a strong equity market. Additionally, UBS expressed optimism about other stocks in China's retail sector, indicating a favorable market environment for these companies. The upgrade of LAOPU GOLD to Buy was based on anticipated valuation pressure and potential product price hikes that could support short-term sales and gross margins.
Morgan Stanley
Morgan Stanley
Overweight
maintain
$9
2025-10-16
Reason
Morgan Stanley
Morgan Stanley
Price Target
$9
2025-10-16
maintain
Overweight
Reason
Morgan Stanley's analyst rating for HANG LUNG PPT (00101.HK) was maintained at Overweight due to improved fundamentals and a narrower net asset value (NAV) discount, which decreased from 60% to 50%. The report highlighted a positive trend in the Group's retail business in mainland China, specifically noting a significant increase in tenant sales at Shanghai's Grand Gateway 66 and Plaza 66 in 3Q25 compared to the previous half of the year. This improvement in sales performance, along with key developments such as the opening of new stores, contributed to the positive outlook and the upward adjustment of the target price from $9 to $10.5.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
